HOME_PAGE_HEADER_CONTENT

A female patient and a female physician, representing different ethnicities in conversation A female patient and a female physician, representing different ethnicities in conversation

Passion for Innovation.
Compassion for Patients.®

Creating New Standards of Care

Creating New Standards of Care

We create essential medicine for longer, better lives.

Learn More About Our Purpose

RecentStoryCarousel

Our Stories

Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories

Let Me Tell You About My Aunt Maryann

Translating facts into memorable stories is a powerful craft. Discover how Daiichi Sankyo communications leader Kim Wix inspires action via storytelling.

Learn more
Translating the Science of ADCs for Patients with Cancer 

Informed patients are empowered patients. Which is why helping people with cancer understand their disease, as well as how available treatment options might work for them, is a critical focus of our patient advocacy efforts.

Learn more

Transforming Science into Medicines

Transforming Science into Medicines

By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.

Learn More About Our Science
2 women in lab coats looking at a sample

Dxd Section

Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology

DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.

Explore the DXd ADC Technology Website

Featured News

What's New

Read our press releases and learn more about our latest breakthroughs in medicine. View More News

Mon Apr 21 00:00:00 GMT-05:00 2025

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient population versus current first-line standard of care plans for regulatory submissions are underway.

Learn more

Mon Mar 31 00:00:00 GMT-05:00 2025

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) versus trastuzumab in combination with platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.

Learn more

New Home Pipeline

A Pipeline Pushing Us to Become a Global Leader in Oncology

Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.

Learn More About Our Medicines

New Home With Purpose

Work with a Purpose

Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.

Join Our Team
Office employee sitting listening to conversation